硫酸镁与聚乙二醇4000对老年冠心病新发功能性便秘的通便效果观察  

Efficacy and Safety of Magnesium Sulfate Preparations and Macrogol 4000 on New-onset Constipation during Hospitalization among Patients with Coronary Heart Disease

作　　者：龙小兰[1] 黄楷森[1] 熊国均[1] 

机构地区：[1]德阳市人民医院心血管内科,四川德阳618000

出　　处：《华西医学》2013年第5期764-766,共3页West China Medical Journal

摘　　要：目的对比研究口服硫酸镁与聚乙二醇4000对老年冠心病新发便秘患者的通便效果及安全性。方法 2010年10月-2012年4月将158例冠心病新发便秘老年患者按入院单双号时间随机分为两组,试验组88例患者口服硫酸镁,对照组70例服用聚乙二醇4000散剂,观察两组患者服药后排便时间、排便效果及服药后不良反应。结果两组排便时间比较,试验组67例(76.14%)患者在服药6 h内开始排便,对照组则仅有35例(50.00%)在该时间段排便,试验组人均排便量及总有效率优于对照组。结论硫酸镁治疗老年冠心病新发便秘疗效确切,不良反应低,不失为一种临床解除新发便秘安全、有效的药物。Objective To investigate the clinical efficacy and safety of magnesium sulfate preparations and macrogol 4000 on new-onset constipation during hospitalization among patients with coronary heart disease. Methods A total of 158 patients with new-onset constipation admitted with a principal diagnosis of coronary heart disease between October 2010 and April 2012 were included in this randomized, comparative trial. They initially received either 33% magnesium sulfate preparations 30 ml or macrogol 4000 20g. Patients were assessed for time distribution of first evacuation, average stool quality, defecation efficacy and side effect. Results Sixty-seven （76.14%） patients in the magnesium sulfate group defecated in the initial 6 hours after taking the agent and 35 （50.00%） in the macrogol 4000 group, and the difference between them was significant （P 〈 0.05）. The average stool quality and defecation efficacy between the two groups were significantly different. The incidence of adverse events was similar. Conclusion Magnesium sulfate preparations treatment was safe and effective for new-onset constipation during hospitalization among patients with coronary heart disease.

关 键 词：新发便秘 硫酸镁 聚乙二醇4000 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]